[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,517,648
  • Shares Outstanding, K 60,981
  • Annual Sales, $ 521,310 K
  • Annual Income, $ -23,360 K
  • EBIT $ -796 M
  • EBITDA $ -770 M
  • 60-Month Beta 0.52
  • Price/Sales 12.42
  • Price/Cash Flow 2,102.04
  • Price/Book 26.95

Options Overview Details

View History
  • Implied Volatility 39.09% (-5.14%)
  • Historical Volatility 46.48%
  • IV Percentile 15%
  • IV Rank 10.63%
  • IV High 99.96% on 04/10/26
  • IV Low 31.86% on 08/21/25
  • Expected Move (DTE 2) 0.94 (0.83%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 273
  • Volume Avg (30-Day) 924
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 5,932
  • Open Int (30-Day) 9,299
  • Expected Range 112.27 to 114.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.75
  • Number of Estimates 6
  • High Estimate $-0.37
  • Low Estimate $-1.47
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -525.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.34 +28.44%
on 05/04/26
114.01 -0.48%
on 05/13/26
+16.97 (+17.59%)
since 04/13/26
3-Month
84.33 +34.54%
on 03/09/26
114.01 -0.48%
on 05/13/26
+10.36 (+10.05%)
since 02/13/26
52-Week
42.89 +164.54%
on 05/23/25
114.01 -0.48%
on 05/13/26
+68.19 (+150.63%)
since 05/13/25

Most Recent Stories

More News
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior...

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate...

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: ...

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

- Q1 2026 net product sales of $159.9 million - 2026 net product sales guidance increased to $660 to $680 million - Volixibat...

MIRM : 112.66 (+5.41%)
Mirum's Volixibat Win Rewrites What Investors Thought This Pipeline Could Actually Deliver

Barchart Research What to Expect from MIRM Earnings MIRM Generated May 5, 2026 Current Price $105.81 EPS Estimate $$-0.40 Consensus Rating Strong Buy Average Move 6.82% Mirum's Volixibat Win Rewrites What...

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

-  Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 point placebo-adjusted (p=

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results...

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026. Mirum will also host a conference call...

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

-Primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 -Favorable safety and tolerability profiles observed ...

MIRM : 112.66 (+5.41%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on April 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards...

MIRM : 112.66 (+5.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 112.98
2nd Resistance Point 110.45
1st Resistance Point 108.66
Last Price 112.66
1st Support Level 104.34
2nd Support Level 101.81
3rd Support Level 100.02

See More

52-Week High 114.01
Last Price 112.66
Fibonacci 61.8% 86.84
Fibonacci 50% 78.45
Fibonacci 38.2% 70.06
52-Week Low 42.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.